Daunorubicin Dosage
This dosage information may not include all the information needed to use Daunorubicin safely and effectively. See additional information for Daunorubicin.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Usual Adult Dose for:
Usual Geriatric Dose for:
Usual Pediatric Dose for:
Additional dosage information:
Usual Adult Dose for Acute Nonlymphocytic Leukemia
< 60 years: 45 mg/m² IV over 2 to 5 minutes once a day on days 1, 2, and 3 for the first course and on days 1 and 2 for subsequent courses) with cytosine arabinoside (ara-C) intravenously once a day (usually for 7 days for the first course and 5 days for subsequent courses) as remission induction therapy.
Usual Adult Dose for Acute Lymphocytic Leukemia
For Remission Induction:
45 mg/m²/day IV on days 1, 2, and 3 (along with vincristine, prednisone, and L-asparginase therapy)
Usual Geriatric Dose for Acute Nonlymphocytic Leukemia
>=60 years: 30 mg/m² IV over 2-5 minutes once a day on days 1, 2, and 3 for the first course and on days 1 and 2 for subsequent courses) with cytosine arabinoside (ara-C) intravenously once a day (usually for 7 days for the first course and 5 days for subsequent courses) as remission induction therapy.
Usual Pediatric Dose for Acute Myeloid Leukemia
As a part of combination therapy: Induction:
30 to 60 mg/m2/day by continuous IV infusion on days 1 to 3 of cycle
or
20 mg/m2/day for 4 days every 14 days
Usual Pediatric Dose for Acute Lymphocytic Leukemia
Acute Lymphocytic Leukemia combination therapy: Remission Induction:
<2 years or <0.5 m2:
1 mg/kg per protocol with frequency dependent on regimen employed.
> 2 years or >0.5 m2:
25 mg/m² IV on day 1 every week (along with vincristine and prednisolone therapy). Generally complete remission will be obtained after 4 courses of therapy. If needed, an additional 1 or 2 courses of therapy may be administered in an effort to obtain a complete remission.
or
25 to 45 mg/m2 on days 1 and 8 of cycle (as a part of combination chemotherapy)
or
30 to 45 mg/m2/day for 3 days every 3 to 4 weeks
Renal Dose Adjustments
Serum Creatinine > 3 mg%: The dose should be 50% of the normal dose.
Liver Dose Adjustments
Serum bilirubin 1.2 to 3 mg/dL or AST 60-180 intl units: The dose should be reduced to 75% of the normal dose.
Serum bilirubin 3.1 to 5 mg/dL or AST > 180 intl units: The dose should be reduced to 50% of the normal dose.
Serum bilirubin > 5 mg/dL: Not recommended to be used.
Dose Adjustments
The dose of daunorubicin may also depend on whether other cytotoxic agents are to be given. Reference to specific protocols is recommended.
Precautions
Because significant renal and/or hepatic impairment can increase the risk of toxicity of daunorubicin, evaluating and maximizing the renal and liver function prior to administration of this drug is recommended. Myocardial toxicity may occur during therapy or months to years after termination of therapy.
Other Comments
The lifetime dosage of daunorubicin should not exceed 10 mg/kg in children less than 2 years of age, 300 mg/m2 in children greater than 2 years of age, and 400 to 600 mg/m2 in adults.
